Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at HC Wainwright

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 468.18% from the company’s previous close.

Several other equities analysts have also commented on CMPX. D. Boral Capital reissued a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Monday, September 16th. Finally, Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $11.80.

Compass Therapeutics Stock Performance

Shares of CMPX stock traded up $0.33 on Wednesday, hitting $1.76. 1,160,645 shares of the company’s stock traded hands, compared to its average volume of 521,074. The stock has a market capitalization of $242.16 million, a price-to-earnings ratio of -4.76 and a beta of 0.92. The company’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $1.44. Compass Therapeutics has a one year low of $0.77 and a one year high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. As a group, sell-side analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently modified their holdings of CMPX. Ground Swell Capital LLC bought a new position in Compass Therapeutics during the 2nd quarter valued at about $124,000. Barclays PLC lifted its position in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares during the period. Renaissance Technologies LLC boosted its holdings in Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after purchasing an additional 70,200 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in Compass Therapeutics in the 3rd quarter worth approximately $79,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Compass Therapeutics during the 2nd quarter valued at $41,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.